代谢组学在儿童肠易激综合征诊治中的研究进展  

Research progress of metabolomics in children with irritable bowel syndrome

作　　者：陈小龙(综述) 江米足(审校)[3] CHEN Xiao-Long;JIANG Mi-Zu(Department of Gastroenterology and Pediatric Endoscopy Center,Children's Hospital,Zhejiang University School of Medicine/National Clinical Research Center for Child Health/National Children's Regional Medical Center,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院儿童内镜中心/国家儿童健康与疾病临床医学研究中心/国家儿童区域医疗中心,浙江杭州310052 [2]嘉善县第一人民医院儿科,浙江嘉兴314100 [3]浙江大学医学院附属儿童医院消化科和儿童内镜中心/国家儿童健康与疾病临床医学研究中心/国家儿童区域医疗中心,浙江杭州310052

出　　处：《中国当代儿科杂志》2024年第9期989-994,共6页Chinese Journal of Contemporary Pediatrics

基　　金：“十四五”国家重点研发计划项目(2023YFC2706500);课题(2023YFC2706504);国家中心自主立项项目(G20A0008)。

摘　　要：肠易激综合征(irritable bowel syndrome,IBS)是一种常见的功能性胃肠病,主要表现为腹痛、腹泻、便秘以及消化不良等症状。由于其病因和发病机制尚不清楚,并且缺乏特异性的生物标志物,使其临床诊断和治疗仍然存在较大困难。近年来,代谢组学技术因其无创、高通量、高精度、高可重复性等特点,在疾病诊断、治疗及预后评估方面得到了广泛应用。代谢组学技术有望为IBS的生物学机制研究、诊断及治疗提供新思路和方法。该文综述近年代谢组学在IBS中的应用及研究进展,并探讨其在儿童IBS临床诊断和治疗中的潜在应用价值。Irritable bowel syndrome(IBS)is a common functional gastrointestinal disorder characterized by symptoms such as abdominal pain,diarrhea,constipation,and indigestion.Given its unclear etiology and pathogenesis,and the absence of specific biomarkers,clinical diagnosis and treatment of IBS continue to pose significant challenges.In recent years,metabolomics technology,known for its non-invasive,high-throughput,high-precision,and highly reproducible features,has been widely applied in the diagnosis,treatment,and prognosis of various diseases.Therefore,metabolomics technology is expected to offer novel insights and methodologies for the biological mechanism research,diagnosis,and treatment of IBS.This article reviews recent advancements in the application of metabolomics to IBS,exploring its potential value in the clinical diagnosis and treatment of children with this condition.

关 键 词：肠易激综合征 代谢组学 生物标志物 代谢通路 儿童 

分 类 号：R725.7[医药卫生—儿科]